ASCO daily highlights: Monday 3rd June
Read our 5 key highlights from day 4 at ASCO:
- BRAF V600E mCRC continues to be a disease with a poor prognosis in need of novel therapeutic approaches. Biomarker-driven patient stratification may be needed to further identify potential patients among the BRAF V600E mCRC cohort who might benefit from ERAS-007 treatment.
- Highly sensitive techniques is needed to detect small fragments of tumor-specific alterations in the background of cell-free DNA from non-cancerous cells, and prospective validation is required before such assays can be used to guide therapy outside of the clinical trial setting.
- TUC+Trasis is an important chemotherapy-free treatment option in HER2+ mCRC. Results from upcoming phase III MOUNTAINEER trial will support its use as a 1L treatment (dual HER2 targeted therapy) for patients with HER2+ mCRC.
- Results from CodeBreaKsupport trial support the use of soto960+pani as a potential SOC for patients with
chemorefractory KRAS G12C-mutated mCRC. Not all targeted therapies will show superior therapeutic activity. Treatment choices should be carefully evaluated in combination with an individual's biomarker testing results and treatment history. - ADC target expression matter: selecting patients based on target (c-Met) expression is clinically relevant and criticalpatient selection for ABBV-400 in CRC patients.
If you missed us at ASCO, and would like to learn more about how we can support your commercialization strategy, contact us here: Contact Us - Diaceutics
References:
Abstract 3517 “Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study.”
Abstract 3009 “Performance characteristics of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies.”; abstract 3010 “Personalized cell-free tumor DNA analysis for patients with HNSCC: Liquid biopsy for minimal residual disease detection in head and neck squamous cell carcinoma (LIONESS).”; abstract 3011 “Circulating tumor cells and tumor DNA in patients with resectable colorectal liver metastases: The MIRACLE.”
Abstract LBA3510 “Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).”
Abstract 3509 “Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).”
Abstract 3515 “First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer.”
